Puma Biotechnology, Inc. — FY2011 Form 10-K
Reporting period: Year ended December 31, 2011. This is an annual filing, not a standalone fourth-quarter report. Puma was a development-stage oncology biopharmaceutical company; its October 2011 reverse merger with Innovative Acquisitions Corp. made Puma the accounting acquirer. The 2010 comparison covers only September 15–December 31, 2010, so periods are not directly comparable.
Financial results and liquidity
| Metric | FY2011 | Comparable period |
|---|---|---|
| Product revenue | None | None |
| Operating expenses | $10.16 million | $6,931 |
| Net loss | $10.23 million | $6,931 |
| Operating cash flow | $(1.83) million | $(6,931) |
| Investing cash flow | $(1.75) million | None |
| Financing cash flow | $56.95 million | $6,931 |
| Cash and cash equivalents at year-end | $53.38 million | None |
Year-end total assets were $55.40 million, including $1.05 million of restricted cash securing a lease letter of credit. Total liabilities were $1.03 million, chiefly accrued expenses and deferred rent; the filing reports no interest-bearing debt at year-end. Stockholders’ equity was $54.37 million. Profit margins are not meaningful because there were no product sales.
FY2011 G&A expense was $9.32 million, including approximately $7.59 million of noncash expense for a CEO anti-dilution warrant. R&D expense was $826,372. The company raised approximately $60 million gross in private equity placements in October and November, at $3.75 per share; reported net proceeds from common stock issuance were $56.74 million.
Changes, outlook, and material items
- Expenses rose substantially as Puma licensed drug candidates, completed the reverse merger, hired staff, and established its public-company infrastructure. The 2010 comparison reflects only the company’s short inception period.
- Management estimated 2012 R&D spending of $20–25 million and G&A spending of $5–6 million over the next 12 months. It stated cash was expected to fund operations for at least 18 months; the notes describe funding clinical development through 2012 and into 2013. The company expected continued losses and no product approval until approximately 2015, assuming no unforeseen safety issues.
- The pipeline comprised oral and intravenous neratinib (PB272) and PB357. Planned work included Phase II studies in HER2-positive breast and gastric cancer, an IND filing for intravenous neratinib, and evaluation of PB357. These were plans, not assured milestones.
- In October 2011, Puma announced it would terminate enrollment and wind down Pfizer’s NEfERTT and ExteNET trials; Puma expected to bear trial wind-down activities during 2012 and beyond. Pfizer continued certain existing studies at its expense through year-end, with some support at Puma’s expense in Q1 2012.
- The Pfizer license carries contingent milestone payments totaling approximately $187.5 million if all milestones are achieved, plus royalties of approximately 10%–20% of net sales if products are commercialized. The filing does not present these contingent milestones as current debt.
- The company had no approved products, product revenue, or established sales or manufacturing capability. It depends on future financing, clinical and regulatory success, third-party researchers and manufacturers, and its Pfizer license. Management’s financing outlook is subject to uncertainty and additional capital may be required.
- Other investor-relevant exposures include a seven-year office lease with disclosed future minimum payments totaling $3.82 million, contingent investor anti-dilution warrants, and potential dilution. A registration statement covering resale of 16 million shares became effective in February 2012. The common stock had no established trading market at filing.
The audit opinion stated that the financial statements fairly presented the company’s financial position and results under U.S. GAAP. Management reported disclosure controls and internal control over financial reporting effective at December 31, 2011; the auditor did not attest to internal-control effectiveness.
Key facts for investors to verify
- Actual 2012 R&D and G&A spending, cash burn, and whether the stated cash runway assumptions held.
- Clinical-trial progress, results, safety findings, and costs—including wind-down obligations for the discontinued Pfizer-sponsored studies.
- Terms and potential dilution of the CEO warrant and investor anti-dilution warrants, and the impact of registered-share resales.
- Any financing plans or capital needs, and the company’s ability to meet Pfizer license development obligations and contingent milestones.
- Third-party manufacturing and trial-provider arrangements, and the status of regulatory submissions and product-development timelines.